Aoxing Pharmaceutical
AXN
AXN was delisted on the 16th of October, 2017.
3 hedge funds and large institutions have $16K invested in Aoxing Pharmaceutical in 2013 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and 0 closing their positions.
50% more funds holding
Funds holding: 2 → 3 (+1)
0% more ownership
Funds ownership: 0.13% → 0.13% (+0%)
100% less capital inflows, than outflows
Capital inflows: $0 | Capital outflows: $142
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$142 |
AXN Hedge Fund Activity: Q4 2013 in Review
3 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Aoxing Pharmaceutical (AXN) for Q4 2013, worth a combined $16K — down 5.9% from $17K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new AXN positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.
The largest seller was Citadel Advisors, cutting an estimated $142.
- 3 institutional investors held Aoxing Pharmaceutical (AXN) as of Q4 2013, up from 2 in Q3 2013.
- Funds reported $16K of Aoxing Pharmaceutical stock for Q4 2013, down 5.9% quarter-over-quarter.
- 1 fund opened new Aoxing Pharmaceutical positions in Q4 2013 and 0 closed out, a net change of +1 holder.
- The largest Aoxing Pharmaceutical seller in Q4 2013 was Citadel Advisors, an estimated $142 sold.
Based on aggregated 13F filings for Q4 2013.